Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321767 | 0.91 | MTNR1A (0.43) | MTNR1AMTNR1B | |
| SCHEMBL4320915 | 0.87 | MTNR1A (0.41) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL4307328 | 0.86 | MTNR1A (0.40) | MTNR1AMTNR1B | |
| SCHEMBL4312896 | 0.85 | MTNR1A (0.42) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6047774 | 0.85 | MTNR1A (0.41) | MTNR1AMTNR1BCRHR1CNR1CNR2 | |
| SCHEMBL4309188 | 0.84 | MAPT (0.39) | MTNR1AMTNR1BCRHR1CNR1CNR2 | |
| SCHEMBL4316476 | 0.84 | KDM4E (0.42) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL4307287 | 0.83 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL4309625 | 0.82 | TSPO (0.43) | MTNR1AMTNR1B | |
| SCHEMBL4314970 | 0.82 | TSPO (0.41) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | MTNR1A 425/4885MTNR1B 372/4885CRHR1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.